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Abstract
Human immunodeficiency virus type-1 (HIV-1) particles incorporate a trimeric envelope complex (Env) made of gp120 (SU) and gp41
(TM) heterodimers. It has been previously established that soluble CD4 (sCD4) interaction leads to shedding of gp120 from viral particles,
and that gp120 may also be easily lost from virions during incubation or particle purification procedures. In the design of HIV particle or
pseudovirion-based HIV vaccines, it may be important to develop strategies to maximize the gp120 content of particles. We analyzed the
gp120 retention of HIV-1 laboratory-adapted isolates and primary isolates following incubation with sCD4 and variations in temperature.
NL4-3 shed gp120 readily in a temperature- and sCD4-dependent manner. Surprisingly, inactivation of the viral protease led to markedly
reduced shedding of gp120. Gp120 shedding was shown to vary markedly between HIV-1 strains, and was not strictly determined by
whether the isolate was adapted to growth on immortalized T cell lines or was a primary isolate. Pseudovirions produced by expression of
codon-optimized gag and env genes also demonstrated enhanced gp120 retention when an immature core structure was maintained.
Pseudovirions of optimal stability were produced through a combination of an immature Gag protein core and a primary isolate Env. These
results support the feasibility of utilizing pseudovirion particles as immunogens for the induction of humoral responses directed against
native envelope structures.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) en-
velope glycoprotein complex (Env) consists of two sub-
units, the surface subunit gp120 (SU) and the transmem-
brane subunit gp41 (TM). Env is synthesized as a single
glycoprotein precursor, gp160, and is assembled into oli-
gomers (Pinter et al., 1989; Schawaller et al., 1989). These
envelope oligomers have been shown to be trimeric com-
plexes on the surface of cells and on viral particles (Chan et
al., 1997; Kwong et al., 2000). During exocytic transport to
the plasma membrane, the gp160 precursors are cleaved at
a conserved site by cellular furin-like proteases (Earl et al.,
1990; Willey et al., 1988). The SU-TM heterodimers that
make up the heterotrimeric complex are linked by nonco-
valent interactions (Willey et al., 1988). The envelope pro-
tein complex plays a key role in mediating viral tropism
through the specific binding of gp120 to the receptor CD4
molecule and to coreceptor molecules on the cell surface
(Clapham et al., 1991; Dalgleish et al., 1984; Klatzmann et
al., 1984; Lasky et al., 1987; Maddon et al., 1986). Follow-
ing receptor and coreceptor binding, the fusion peptide
region of TM interacts with the target membrane, and con-
formational changes occur in the TM subunit that lead to
apposition of the viral and cellular membranes (Bosch et al.,
* Corresponding author. Vanderbilt University School of Medicine,
Pediatric ID, D-6201 MCN, Nashville, TN 37232-2581. Fax:1-615-322-
6782.
E-mail address: paul.spearman@vanderbilt.edu (P. Spearman).
R
Available online at www.sciencedirect.com
Virology 314 (2003) 636–649 www.elsevier.com/locate/yviro
0042-6822/03/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0042-6822(03)00467-7
1989; Eiden and Lifson, 1992; Freed et al., 1990; Sattentau
and Moore, 1991; Slepushkin et al., 1992).
Recombinant, soluble CD4 (sCD4) is capable of binding
to HIV-1 gp120 in a manner similar to that of full-length
CD4. sCD4 consists of the two N-terminal immunoglobu-
lin-like domains of the ectodomain of CD4, and can neu-
tralize HIV-1 infectivity and inhibit virus-induced syncy-
tium formation (Deen et al., 1988; Fisher et al., 1988;
Hussey et al., 1988; Traunecker et al., 1988). sCD4-depen-
dent HIV-1 neutralization can occur through two mecha-
nisms. First, sCD4 can interact with the CD4 binding site on
gp120 and thereby prevent gp120 from binding to receptor
CD4 molecules on the target cell membrane (Lasky et al.,
1987). Second, sCD4 has been demonstrated to induce the
nonreversible loss of gp120 from viral particles (Hart et al.,
1991; McKeating et al., 1991; Moore et al., 1990, 1991b).
Gp120 loss for lab-adapted strains of HIV-1 occurs in a
sCD4 concentration-dependent manner (Hart et al., 1991;
Kirsh et al., 1990; Moore et al., 1990). It has also been
shown that the HIV-1 envelope glycoprotein complex is
dissociated from HIV particles in response to elevations of
temperature or extremes of pH (Fu et al., 1993), even in the
absence of sCD4 interaction.
Primary isolates of HIV-1 differ markedly from isolates
that have been adapted to growth on immortalized T cell
lines. Primary HIV-1 isolates are relatively resistant to neu-
tralization by polyclonal sera from HIV-1 infected individ-
uals and resist neutralization by many monoclonal antibod-
ies that neutralize laboratory-adapted HIV-1 strains
(Mascola et al., 1994; Matthews, 1994; Moore et al., 1995).
sCD4 also readily neutralizes laboratory-adapted strains,
while primary isolates require much higher concentrations
of sCD4 to obtain similar levels of neutralization (Ash-
kenazi et al., 1991; Daar et al., 1990; Moore et al., 1993,
1992; O’Brien et al., 1994). These data suggest that neu-
tralization epitopes exposed on gp120 molecules on the
surface of laboratory-adapted isolates are normally con-
cealed in primary isolate viruses, and imply that one adap-
tion to T cell line replication is conformational alteration of
gp120 to a more neutralization-friendly state. The enhanced
epitope exposure on laboratory-adapted isolates may be due
to adaptive changes in Env that optimize the CD4–envelope
interaction in the absence of selective pressure produced by
the humoral immune response.
Attempts to elicit humoral responses against HIV using
recombinant envelope glycoprotein molecules have thus far
failed to elicit strong cross-reactive neutralizing antibodies
against primary isolates (Cohen, 1993; Mascola et al., 1996;
Sawyer et al., 1994). Responses against recombinant gp120
molecules are generally strongest against regions of gp120
that are occluded in the native trimer, and are thus not
capable of neutralization of the viral particle (York et al.,
2001). Strategies to overcome this include the engineering
of molecules that more closely resemble the native trimeric
complex through introduction of disulfide bonds for gp120-
gp41 stabilization (Binley et al., 2000; Sanders et al., 2000),
disruption of the SU/TM cleavage site through mutagenesis
(Earl et al., 1994; Stamatatos et al., 2000; VanCott et al.,
1997), or through the engineering of heterologous leucine
zipper domains into gp41 to promote trimer formation
(Yang et al., 2000, 2002). An oligomeric, V2-deleted ver-
sion of the SF162 glycoprotein was recently shown to elicit
antibodies in macaques with neutralizing activity against a
limited number of HIV-1 primary isolates (Barnett et al.,
2001). Another approach to this problem is to design HIV
pseudovirions composed of Gag and Env proteins (Gheysen
et al., 1989; Haffar et al., 1990). Pseudovirions allow the
native envelope trimer to be presented on a noninfectious
particle platform. Promising results with pseudovirions
have been reported in the literature, including the ability of
Env on pseudovirions to elicit neutralizing antibodies
against a homologous primary isolate virus (Montefiori et
al., 2001). The production of pseudovirions that incorporate
Env complexes in an efficient and stable manner is thus a
worthwhile goal for vaccine design.
In this study, we examined the retention of gp120 on
laboratory-adapted HIV-1 isolates and primary isolates fol-
lowing sCD4 addition and temperature variation. We then
examined HIV-1 pseudovirions incorporating primary iso-
late envelope glycoproteins for their gp120 retention under
similar conditions. We demonstrate that NL4-3 virions with
an uncleaved core have an increased retention of gp120
following sCD4 addition and exposure to increasing tem-
peratures. Differences in gp120 shedding among different
isolates were strain specific, and did not strictly correlate
with lab-adapted vs primary isolate classification. Finally,
we show that HIV-1 pseudovirions incorporating primary
isolate envelope glycoproteins do not readily shed gp120,
and that gp120 retention on pseudovirions can also be op-
timized through the use of an immature Gag core. These
results support the design of pseudovirion immunogens ca-
pable of presenting native Env complexes to elicit humoral
immune responses.
Results
Effect of sCD4 and temperature increases on gp120
shedding by NL4-3 virions
Previous data have demonstrated that sCD4 leads to
shedding of gp120 from lab-adapted strains of HIV-1. In
order to determine the effect of sCD4 interaction on enve-
lope stability, concentrated NL4-3 virions were incubated
with increasing concentrations of sCD4 (0-10 g/mL) for
2 h at 0, 4, and 37 °C. These samples were then purified by
centrifugation through a sucrose cushion, and the particle-
associated envelope concentration was determined using a
gp120 capture ELISA. A significant dissociation of gp120
from NL4-3 virions was observed with increasing temper-
ature and with increases in sCD4 concentration (Fig. 1A).
The dissociation of gp120 from NL4-3 virions in the pres-
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Fig. 1. Effect of sCD4 concentration and temperature elevation on NL4-3 virion envelope shedding. Virions were incubated with increasing sCD4
concentrations at 0 (closed squares), 4 (open circles), and 37 °C (closed triangles) for 2 h. Virus particles were subsequently purified by centrifugation through
a sucrose cushion, and the virion gp120 content determined using a gp120 capture ELISA. Envelope shedding was calculated as percent virion bound gp120
remaining in the postincubation viral pellet. 100% retention was set as the amount of gp120 retained at 0 °C in the absence of sCD4. Results are representative
of three independent experiments. (A) NL4-3 virion gp120 retention with increasing sCD4 concentration. (B) NL4-3 gp120 retention seen with increasing
temperature in the absence of sCD4. (C) NLPr gp120 retention with increasing sCD4 concentration. (D) NLPr gp120 retention at differing temperatures
in absence of sCD4. (E) NL4-3 virions harvested from H9 cell supernatants were examined for gp120 retention in an identical manner to that in A. (F) NL4-3
virions harvested from H9 cell supernatants examined for gp120 retention at increasing temperatures in the absence of sCD4.
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ence of sCD4 was biphasic, with the steepest dissociation
occurring between 0 and 1 g/ml sCD4. NL4-3 virions shed
significant amounts of gp120 as a result of sCD4 binding at
all temperatures tested. Maximal shedding of gp120 was
observed at 37 °C with 10 g/mL sCD4, which resulted in
greater than 80% dissociation from NL4-3 virions (Fig. 1A,
grey diamonds). It is interesting to note that gp120 was even
shed from NL4-3 virions at 0 °C in a sCD4 dependent
manner (Fig. 1A, filled squares). Gp120 was also lost from
NL4-3 virions in a temperature-dependent manner in the
absence of sCD4, indicating that heat alone can lead to
significant gp120 loss from this isolate (Fig. 1B). A signif-
icant loss of gp120 was seen for virions incubated at 4 °C,
as compared with virions that were strictly maintained in
liquid ice (0 °C, Fig. 1B). When increasing temperatures
were employed, an additional increment in gp120 shedding
was not demonstrated until the temperature was increased to
50 °C or higher.
The degree of shedding of gp120 from NL4-3 virions in
response to temperature increase and interaction with sCD4
may be detrimental to particle-based vaccine strategies. To
test the hypothesis that an immature Gag core may act to
stabilize gp120 on the virion, as suggested by a recent report
(Wyma et al., 2000), we performed identical experiments
with an NL4-3 provirus containing inactivating substitu-
tions of the protease active site (NLPr). Maximal shedding
of gp120 from NLPr virions was observed at 37 °C and 10
g/mL sCD4, but resulted in only a 23% loss of gp120 (Fig.
1C). Loss of gp120 seen with NLPr virions was remark-
ably less at all temperatures and sCD4 concentrations than
that seen with NL4-3 (compare Fig. 1A and C). NLPr
virions also displayed enhanced stability to temperature
increases in the absence of sCD4, with no substantial loss
until incubated at temperature of greater than or equal to 50
°C (Fig. 1D). We conclude that the immature Gag core
resulted in a significant enhancement of the stability of
gp120 on virions.
We noted during these experiments that the total amount
of gp120 on virions produced by transfection of 293T cells
exceeded that of virus grown in the cell line H9 (Table 1).
To determine if the mode of production or amount of in-
corporated gp120 accounts for the substantial shedding ob-
served for NL4-3 virions, we analyzed the stability of gp120
on virus that was grown in H9 cells. NL4-3 grown in H9
cells rapidly lost gp120 in a temperature- and sCD4-depen-
dent manner, with a 60% loss of gp120 at 37 °C and 10
g/ml sCD4 (Fig. 1E). Gp120 was also shed in a tempera-
ture-dependent manner in the absence of sCD4 (Fig. 1F).
Results with H9-derived virus were thus similar to those
seen with virus produced by transfection, although slightly
less in degree. We conclude that a small portion of the
extreme amount of gp120 loss shown in Fig. 1A could be
attributable to the virus production method, but that NL4-3
produced by either method demonstrates significant shed-
ding. Taken together, these results indicate that NL4-3
readily sheds gp120 unless stabilized through the presence
of an uncleaved Gag core.
The gp120 ELISA used in our experiments was carefully
validated using a series of laboratory-adapted and primary
isolate viruses and recombinant proteins (data not shown).
However, in order to further validate our results concerning
the enhancement of envelope complex stability by the im-
mature virion core, we analyzed NL4-3 and NLPr virions
using autoradiographic analysis of particles incubated under
varying conditions of temperature and concentrations of
sCD4. Visual inspection of gp120 bands present on the
autoradiograph from this experiment indicates that shedding
occurred in a sCD4-and temperature-dependent manner
(Fig. 2A). Less gp120 shedding was apparent for NLPr
(Fig. 2B). To quantify the differences observed, phospho-
rimager analysis was performed on the gels from this ex-
periment. These experiments revealed that NL4-3 virions
lost 75% of gp120 when incubated with 10 g/mL sCD4 at
37 °C (Fig. 2C). NLPr virions demonstrated enhanced
stability of particle-incorporated gp120 as compared with
NL4-3 virions at both 0 and 37 °C (Fig. 2D). It is important
to note that the relative amounts of gp160 on viral particles
of NL4-3 or NLPr particles were roughly similar, indicat-
ing that retention of uncleaved Env was not responsible for
the differences seen in shedding of gp120 by the ELISA
analysis. This analysis is in agreement with the ELISA data
presented in Fig. 1, and further supports the finding that
uncleaved core stablizes gp120 on virions.
Stability of gp120 on primary HIV-1 isolates vs
laboratory-adapted isolates
The profound shedding of gp120 observed for NL4-3
supported previous work indicating that this property is
common to laboratory-adapted HIV isolates (Groenink et
al., 1995; O’Brien et al., 1994). We next sought to confirm
the finding that primary isolates of HIV retain gp120 in an
enhanced manner, as this would suggest that primary isolate
Env may be desirable on pseudovirion-based immunogens.
Table 1
Gag:Env ratio of HIV-1 virions and pseudovirions
Strain Gag:Env ratio Tropism
Virions
NL4-3 71:1 X4
NL4-3(H9) 323:1 X4
NLPra 2:1 X4
SF162 45:1 R5
BaL 908:1 R5
MN 66:1 X4
Pseudovirions
Gag-Pro/BaL 384:1 R5
55Gag/BaLa 70:1 R5
a Inefficient capture of Pr55Gag by p24 capture ELISA resulted in arti-
ficial lowering of Gag:Env ratio.
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We chose to examine the extent of gp120 shedding exhib-
ited by two primary isolates, SF162 and BaL. These viruses
were grown in PBMCs, concentrated by centrifugation
through a sucrose cushion, and examined using the enve-
lope stability assay already described. Indeed, gp120 on
these isolates was remarkably stable following sCD4 addi-
tion and temperature increases (Fig. 3A–D). BaL gp120 was
stable to sCD4 addition up to 10 g/mL, at 37 °C (Fig. 3A).
BaL also retained nearly 100% of its gp120 upon incubation
in the absence of sCD4; shedding was only evident at
temperatures at or exceeding 50 °C (Fig. 3B). Similar re-
sults were obtained from the examination of the primary
HIV-1 isolate SF162 upon incubation with sCD4 (Fig. 3C)
or upon incubation at a range of temperatures (Fig. 3D). The
reason for the measured increase in pelleted gp120 at 10
g/ml sCD4 over baseline values for this isolate is not yet
clear. This apparent increase was present on repeated ex-
periments, and could be due to some enhancement of viral
pelleting upon addition of high concentrations of sCD4.
Overall, these results are consistent with previous reports
indicating that primary HIV-1 isolate envelope glycoprotein
complexes are relatively resistant to sCD4-induced shed-
ding as compared to lab-adapted strains (Moore et al., 1992,
1991; O’Brien et al., 1994).
The stability of gp120 on primary isolates, together with
the instability of gp120 on NL4-3 virions, suggested that
primary isolates retain gp120 in a much more stable manner
than lab-adapted strains. However, a recent study reported
that gp120 on several lab-adapted strains was also quite
stable (Chertova et al., 2002). To determine if the shedding
of gp120 observed with NL4-3 virions could be generalized
to other lab-adapted isolates, we examined the effect of
Fig. 2. Autoradiographic analysis of sCD4-induced shedding of gp120 from NL4-3 virions. Virions were labeled with [35S]cysteine/methionine and incubated
with the sCD4 concentrations indicated for 2 h at 0 and 37 °C. Virion-associated proteins were immunoprecipitated using HIV patients’ sera and analyzed
by SDS-PAGE and autoradiography. (A) NL4-3 virions. (B) NLPr virions. (C) Phosphorimager quantitation of gp120 from NL4-3 virion results presented
in A. The levels of gp120 present in each lane are presented as a percentage of virion-bound gp120 in the absence of sCD4 treatment. (D) Phosphorimager
quantitation for NLPr virions.
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Fig. 3. Effect of sCD4 concentration and temperature elevation on HIV-1 primary isolates and lab-adapted isolates. Gp120 retention following exposure to
increasing concentrations of sCD4 (left panels) or increasing temperatures in the absence of sCD4 (right panels) was examined by methods identical to those
in Fig. 1. (A) Gp120 retention for primary isolate SF162 with sCD4 exposure. (B) SF162 gp120 retention at varying temperatures in absence of sCD4. (C)
HIV-1 primary isolate BaL gp120 retention with sCD4 exposure. (D) BaL gp120 retention at increasing temperatures in absence of sCD4. (E) Lab-adapted
HIV-1 isolate MN gp120 retention with increasing sCD4. (F) MN gp120 retention at increasing temperatures.
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temperature variation and sCD4 interaction upon the gp120
content of the lab-adapted strain MN. MN was found to be
resistant to sCD4 induced shedding of gp120 up to sCD4
concentrations of 10 g/ml at 37 °C (Fig. 3E). Furthermore,
MN retained its envelope glycoproteins when subjected to
temperature elevations up to 37 °C. MN, like the primary
isolates examined, begin to shed gp120 only at or exceeding
50 °C. These results indicate that both lab-adapted and
primary isolate envelope glycoprotein complexes can ex-
hibit stability to sCD4 and kinetic energy increase. Because
NL4-3 shed gp120 readily, while MN did not, it cannot be
concluded that all lab-adapted strains of HIV-1 are prone to
sCD4-induced shedding of gp120.
Gag-Env ratio on virions and pseudovirions
We considered the possibility that the total amount of
gp120 on virions and pseudovirions may relate to gp120
retention. For example, if NL4-3 produced by transfection
of 293T cells incorporated much higher amounts of gp120
than primary isolates, it could have some aberrantly incor-
porated or “loosely-associated” gp120 that is more readily
shed. To test this hypothesis, we measured the gp120 and
p24 content of each of the purified virion and pseudovirion
particles employed in our studies (Table 1). NL4-3 pro-
duced in 293T cells was found to have a molar ratio of
Gag-to-Env of 71:1. This is very similar to the 60:1 Gag-
to-Env ratio determined by Chertova and co-workers (Cher-
tova et al., 2002), and also agrees with an earlier report for
T cell line adapted viruses in which ratios between 70:1 and
297:1 were observed (O’Brien et al., 1994). Therefore, the
amount of gp120 on the surface of the virus derived from
293T cells was not excessive, and this should not account
for gp120 shedding. NL4-3 virions purified from H9 super-
natants had a four- to fivefold decrease in gp120 as com-
pared with those from 293T (Table 1), yet the shedding of
gp120 was comparable (Fig. 1C). We found that Gag-to-
Env ratios varied from 45:1 (SF162) to 908:1 (BaL) for the
viruses used in our study. The ratios determined for NLPr
and Pr55Gag/BaL are unfortunately not comparable, as we
found that the uncleaved Gag was inefficiently captured by
our p24 ELISA. However, it is clear that the amount of Env
on the particle surface was unrelated to the categorization of
a virion as lab-adapted or primary isolate in origin. It is also
evident that stability of gp120 on the particle surface does
not correlate with Gag-to-Env ratio.
Gradient analysis of virion and pseudovirion gp120
incorporation
We performed sucrose density gradient analysis in order
to demonstrate that the gp120 measured in shedding exper-
iments was present on virion or pseudovirion particles.
Metabolically labeled virions and pseudovirions were sep-
arated by density centrifugation and then immunoprecipi-
tated using HIV patient sera prior to analysis by SDS-
PAGE and autoradiography. Note that the exposure times
were designed to demonstrate the gp120 bands clearly,
resulting in oversaturation of p24 or Pr55Gag signal on these
autoradiograms. All particles peaked at the accepted retro-
viral density of 1.16–1.18 g/mL (Fig. 4A–D). A majority of
the particle-associated envelope glycoprotein seen on both
virions and pseudovirions was present in the cleaved
(gp120) form. The amount of gp120 incorporated on
pseudovirions as assessed by Env/Gag ratios was quite
similar to that of HIV-1 virions (Fig. 4 and Table 1). Little
gp120 was found in gradient fractions other than those of
retroviral particle density, indicating that the gp120 mea-
sured in this study was not significantly confounded by
measurement of aggregates of gp120 or of gp120 on mi-
crovesicles.
Effect of sCD4 addition and heat on stability on Gag-
Pro-Env and Gag-Env pseudovirions
Pseudovirion-based vaccines should be able to present
HIV-1 envelope glycoproteins in a native, oligomeric state,
and thus represent a promising vaccine strategy. We pro-
duced both mature and immature HIV-1 pseudovirions in-
corporating BaL Env through transfection of codon-opti-
mized Gag and Env expression plasmids. Mature (cleaved)
pseudovirions were produced through expression of Gag
and protease, and are referred to as Gag-Pro/Bal pseudoviri-
ons, while immature (uncleaved) pseudovirions were pro-
duced by expression of Pr55Gag in the absence of protease,
and are referred to as Pr55Gag/Bal pseudovirions.
Pseudovirions were then examined for gp120 stability in
experiments similar to those already described. Gag-Pro/
BaL pseudovirions were relatively resistant to sCD4 addi-
tion at the temperatures tested, shedding a maximum of 22%
at 10 g/mL sCD4, 37 °C (Fig. 5A). In response to increas-
ing temperatures alone, the Gag-Pro/BaL particle shed only
20% of its envelope glycoprotein, and shed 50% of gp120
when the temperature was raised to 50 °C (Fig. 5B).
Pr55Gag/BaL pseudovirions demonstrated enhanced gp120
stability as compared to mature particles containing the
same envelope. This finding was most apparent in the re-
tention of gp120 at increasing temperatures (compare Fig.
5B and D), but was also seen to a small degree with
increasing sCD4 concentrations (compare 4 °C curves in
Fig. 5A and C). These results support the differential shed-
ding of gp120 observed with NL4-3 and NLPr. The
smaller difference observed in retention of gp120 seen in
this case is likely due to the inherently more stable primary
isolate BaL Env employed. Importantly, these results sug-
gest that pseudovirion vaccine designs may benefit in gp120
stability from the use of an immature Gag core combined
with a primary isolate HIV-1 envelope glycoprotein.
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Discussion
HIV-1 virus-like particles or pseudovirions represent an
attractive vehicle for the presentation of native, trimeric Env
complexes to the immune system. The present study was
initiated in order to understand the factors that lead to gp120
retention or loss from virions and pseudovirions, in order to
design enhanced pseudovirion-based vaccines. It has been well
established that gp120 is shed from virions following a variety
of manipulations, including exposure to CD4, increases in
temperature, and purification procedures (Fu et al., 1993;
Groenink et al., 1995; McKeating et al., 1991a,b; Moore et al.,
1992; O’Brien et al., 1994). An early attempt to produce an
HIV vaccine through the inactivation and purification of HIV
particles was severely limited by loss of gp120 during the
particle purification process, although the gp120-depleted
product has been further pursued as an immunogen for T cell
responses to Gag (Trauger et al., 1994). If one objective of a
pseudovirion-based vaccine is to produce neutralizing antibody
responses against HIV, then limiting the loss of gp120 from the
pseudovirion surface is a critical goal.
Our results using NL4-3 are consistent with previous
reports indicating that lab strains of HIV are prone to shed
gp120. We demonstrated a dramatic loss of gp120 upon
exposure to sCD4 for this isolate. Kinetic energy was es-
sential in determining the magnitude of gp120 dissociation
during sCD4 incubation. We note for the first time a sub-
stantial difference between 0 °C (samples on wet ice) and a
slight increase in kinetic energy to 4 °C (Fig. 1), although
even greater loss was seen at 37 °C. A substantial loss of
gp120 was also noted following incubation at increasing
temperatures in the absence of sCD4, suggesting that there
is an inherent instability of gp120 on NL4-3 virions. In
contrast to NL4-3, primary isolates demonstrated very little
shedding of gp120 following sCD4 exposure, and retained
substantial amounts of gp120 when incubated at tempera-
tures up to 50 °C. These results were also seen with
pseudovirions produced by expression of codon-optimized
gag and env genes.
We expected that instability of gp120 might be a general
property of laboratory-adapted viral isolates as suggested by
previous work (Moore et al., 1992, 1990). However, we
found that the laboratory-adapted isolate MN retained
gp120 quite efficiently. We interpret this finding to mean
that gp120 loss or retention properties vary by isolate, and
not necessarily by adaptation to growth on T cell lines.
Support for this interpretation comes from a recent report
(Chertova et al., 2002). These investigators used HPLC to
quantitate gp120 and gp41 on purified virions, and found
that little or no SU was shed from both primary isolate and
lab-adapted viruses upon exposure to heat or sCD4. As in
our study, MN did not demonstrate any significant gp120
Fig. 4. Sucrose gradient analysis of virion and pseudovirion-associated gp120. Virions or pseudovirions were metabolically labeled with [35S]cysteine/
methionine, purified by pelleting through a sucrose cushion, and separated on a 20–60% sucrose gradient. Analysis of gradient fractions was carried out by
immunoprecipitation with HIV patients’ sera and autoradiography. (A) NL4-3 virions. (B) NLPr virions. (C) Pseudovirions with a mature core produced
by Gag, protease, and BaL gp160 expression. (D) Pseudovirions with an immature core produced by Pr55Gag and BaL gp160 expression. Peak densities
measured by refractometry are indicated by brackets above the autoradiograms.
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shedding. Thermal stability of gp120 on MN was also dem-
onstrated and agrees with the findings reported here. In
contrast, NL4-3 was examined only by immunoblot in the
Chertova et al. report, and the blot was interpreted as indi-
cating a lack of gp120 shedding. Our data clearly show that
NL4-3 produced by transfection of 293T cells or grown in
H9 cells readily sheds gp120. We conclude from these data
that there are strain-specific differences in gp120 stability
on virions, and that for some isolates (such as NL4-3) gp120
shedding can be profound.
It is important to note that the gp120 retention assay
utilized in this study measured virion-associated gp120 as
the amount of gp120 present on virions following pelleting
through 20% sucrose (before and after temperature incuba-
tions or sCD4 exposure). We chose this method to exclude
from the analysis any gp120 that was already dissociated
from virions at the time of supernatant collection. It is
possible that some virion-associated gp120 was lost in the
initial pelleting step, and that this could result in an under-
estimation of gp120 shedding. However, the amount of
gp120 we detected on the pelleted virions was consistent
with the findings of other investigators for purified HIV
particles (Chertova et al., 2002), suggesting that our treat-
ment was not overly harsh. In addition, our results with
NL4-3 demonstrate that large degrees of shedding were
measured in a very reproducible manner. We conclude that
the pelleting assay is a valid means of measuring gp120
stability on HIV virions and pseudovirions.
Fig. 5. Effect of sCD4 on pseudovirion-associated gp120 retention. (A) Pseudovirions produced by expression of Gag, protease, and BaL gp160 expression
were examined for gp120 retention after incubation with increasing concentrations of sCD4 using methods identical to those for Fig.1. (B) Retention of gp120
following incubation at increasing temperature for Gag-pro/BaL gp160 pseudovirions. (C) Pseudovirions with an immature core (Pr55Gag and BaL gp160
expression) were analyzed for gp120 retention with increasing concentrations of sCD4. (D) gp120 retention with increasing temperature for Gag/BaL gp160
pseudovirions.
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The most striking finding from this report is that an
uncleaved Gag core contributed substantially to gp120 sta-
bility on HIV-1 particles. We hypothesize that the enhanced
envelope stability of NLPr virions is due to interactions
between Gag and the cytoplasmic tail of gp41. An un-
cleaved gag core may enhance gp120 retention by providing
conformational constraints on the ectodomain of the HIV-1
envelope glycoprotein, leading to enhanced gp120 stability.
This hypothesis is supported by a recent report showing that
immature viral cores, but not mature cores, retain gp120
following purification by TX-100 extraction and centrifu-
gation on sucrose gradients (Wyma et al., 2000). The asso-
ciation of gp120 with the viral core in this study required the
gp41 cytoplasmic tail, and the stable retention of gp120 on
cores, could be reproduced by blocking cleavage at the
MA-CA junction. This report and our data support a model
in which a conformational change in gp41 occurs following
cleavage of Gag by the viral protease, leading to a less
stable interaction of gp41 and gp120. However, some iso-
lates, perhaps most primary isolates and some lab-adapted
strains, maintain a strong gp41/gp120 interaction even fol-
lowing cleavage of Gag. For the purpose of developing
pseudovirions as a vaccine platform for Env presentation, it
may be advantageous to use an immature core in order to
avoid gp120 loss, and combining this with a primary isolate
Env or stable T cell Env may produce the most stable
particle.
A secondary goal of our study was to attempt to enhance
the amount of Env present on pseudovirion particles
through overexpression of gp160. Using codon-optimized
gag and env genes, we achieved rapid and high-level ex-
pression. However, we were unable to achieve a significant
decrease in Gag-to-Env ratio despite very efficient expres-
sion of gp160. Our Gag-to-Env molar ratios were remark-
ably similar to those of Chertova et al. (Chertova et al.,
2002). In this study, a ratio of 60:1 was found for almost all
viral isolates tested. These studies suggest that there may be
constraints on the number of Env trimers on viral particles,
and that the limiting factor may not be gp160 expression
itself. Additional studies are needed to address the nature of
these limitations. It may be desirable to utilize Env mole-
cules with deletions of the cytoplasmic tail in order to
enhance the amount of gp120 on the particle surface. We
expect, however, that this would abrogate any benefit in
stability achieved through the use of an uncleaved Gag core.
Overall, we believe that these results are encouraging for
the development of pseudovirion-based vaccines. The use
of an uncleaved Gag core and a primary isolate Env should
result in the production of particles that do not shed gp120
at physiological temperatures, and that can present Env for
induction of a strong humoral immune response. It is pos-
sible that these particles will also demonstrate enhanced
gp120 retention in the presence of adjuvants. Experiments
to address this hypothesis and to determine the immunoge-
nicity of such pseudovirions are presently underway.
Materials and methods
Cell lines and plasmids
The human kidney cell line 293T was maintained in
DMEM (Dulbecco’s modified Eagle medium, high glucose)
supplemented with 10% fetal calf serum, 2 mM L-glu-
tamine, and 2 mM penicillin–streptomycin. H9 leukemic T
cells were obtained from Dr. Robert Gallo through the NIH
AIDS Research and Reference Reagent Program and main-
tained in RPMI 1640 supplemented with 10% fetal calf
serum, 2 mM L-glutamine, and 2 mM penicillin–streptomy-
cin. pNL4-3 is an expression plasmid encoding a complete
infectious clone of HIV-1 (Adachi et al., 1986). pNLPr is
a proviral expression plasmid that contains a triple alanine
substitution in the protease active site. This plasmid was
created in the Aiken lab (Vanderbilt) by inserting a BssHII
to EcoR1 fragment from R9.Pr (Wyma et al., 2000) into
pNL4-3. The construction of codon-optimized SF2 Pr55Gag
expression plasmid pCMVKm2.GagMod.SF2 and SF2 gag-
protease expression plasmid pCMVKm2.GagProtMod.SF2
(GP2) have been previously described (zur Megede et al.,
2000). The envelope expression plasmid pCDNA3.1(Zeo)-
BaLgp160opt was produced by subcloning the codon-opti-
mized BaL sequence from pMR1W1-9 (Fouts et al., 2000)
into pCDNA 3.1(Zeo) (Invitrogen, San Diego, CA).
Virus production and purification
HIV-1 virions were produced as indicated in the Results
section by transfection of proviral DNA in 293T cells,
propagation of virus in H9 cells, or propagation of virus in
PBMC blasts derived from normal donors. Biological
stocks of HIV-1 isolate BaL were obtained from Drs. Su-
zanne Gartner, Mikulas Popovic, and Robert Gallo, MN
from Robert Gallo, and SF162 from Dr. Jay Levy, all
through the NIH AIDS Research and Reference Reagent
Program. For transfections, 10 g of proviral DNA was
transfected into 293T cells on 10 cm2 dishes using the
calcium phosphate/BBS transfection method (O’Mahoney
and Adams, 1994). Typically 10 10 cm2 dishes of 293T
cells were transfected at 30–40% confluence and incubated
at 35 °C, 4% CO2 for 16 h. The cells were washed and fresh
DMEM applied, and further incubation carried out at 37 °C
and 5% CO2 for 48 h prior to harvesting. For labeling
experiments, 75 Ci/ml of [35S]cysteine/methionine was
applied in cysteine and methionine-deficient DMEM, and
labeled viruses were harvested after 24 h. For production of
laboratory-adapted HIV-1 isolates in H9 cells, 5  106 H9
cells were infected with 200 ng of a frozen biological stock
of HIV strains NL4-3 or MN. Virus replication was allowed
to proceed for 7 days, at which time syncytia formation in
the culture was evident. H9 supernatants were then har-
vested, filtered through a 0.45 m filter, and assessed for
p24 and gp120 content. Primary isolates of HIV-1 were
propagated in PHA blasts produced from PBMCs derived
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from HIV-uninfected volunteer donors. In these experi-
ments, 200 ng of primary isolate biological stock was incu-
bated with 5  106 PBMCs. PBMC cultures were main-
tained in RPMI 1640 with 15% FCS and 20 U/mL IL-2, and
virus replication allowed to proceed for 7 days prior to
harvesting. Supernatants were then filtered through a 0.45
m filter. All virus preparations (from 293T, H9, or PBMC)
were purified by ultracentrifugation through a 20% sucrose
cushion (100,000g for 3 h, 0 °C). Viral pellets were then
resuspended in PBS with 0.5% BSA, and 1-mL aliquots
were stored at 80 °C. Each aliquot of virus was thawed
only once and used for a single experiment.
Pseudovirion production and purification
Pseudovirions were produced by cotransfection of 293T
cells with codon-optimized Gag expression construct
pCMVKm2.GagMod.SF2 and codon-optimized Bal gp160 ex-
pression construct pcDNA3.1(Zeo)-BaLgp160opt, or by co-
transfection of codon-optimized Gag-Pro expression construct
pCMV.Km2.GagProtMod.SF2 (GP2) and pcDNA3.1(Zeo)-
BaLgp160opt. Purification and analysis of pseudovirions was
identical to that described for HIV-1 virions above.
Determination of gp120 concentration using a gp120
capture ELISA
The gp120 concentration of HIV-1 virions and
pseudovirions was measured by a capture ELISA similar to
that of Moore and colleagues (Moore et al., 1992). The
anti-gp120 capture antibody, D7324 (Cliniqa, Fallbrook,
CA), was coated onto 96-well plates at a concentration of 4
g/mL in PBS overnight at 37 °C. The plates were blocked
with 5% fetal calf serum in PBS for 1 h at 37 °C. Viruses
were diluted in Env sample diluent (10% FCS, 0.5% Triton
X-100 in PBS) and incubated on D7324-coated plates for
2 h at 37 °C. The amount of captured gp120 was determined
using pooled HIV positive patients’ sera at a dilution of
1:6000 in env sample diluent for 1 h at 37 °C. Detection was
performed using a horseradish peroxidase-conjugated goat
anti-human IgG (Pierce, Rockford, IL) at a dilution of
1:6000 in env sample diluent for 1 h at 37 °C. Colorimetric
analysis was performed using the Immunopure TMB Sub-
strate Kit (Pierce, Rockford, IL) and absorbance was read at
450 nm. Recombinant BaL gp120, obtained from the Divi-
sion of AIDS, NIAID, through the NIH AIDS Research and
Reference Reagent Program was used for the standard
curve. The assay was also calibrated using recombinant MN
gp120 obtained through the same source. The linear detec-
tion of gp120 by this assay was sensitive to less than 10 pg
of gp120.
HIV-1 envelope stability assay
Purified HIV-1 and pseudovirion preparations containing
10–20 ng of particle-associated gp120 were resuspended in
200 L of PBS containing 0.5% BSA and were incubated in
the presence of increasing amounts of sCD4 (Progenics
Pharmaceuticals, Tarrytown, NY) at 0, 4, and 37 °C for 2 h.
Virions were then purified by centrifugation through a 250
l 20% sucrose cushion in a 1.5 ml microfuge tube at
100,000 g for 1.5 h at 0 °C using a Sorvall RP45A rotor.
Purified virions or pseudovirions were then resuspended in
Env sample diluent (10% fetal calf serum, 0.5% Triton
X-100, in PBS) for analysis of gp120 content by previously
described gp120 capture ELISA. Purified HIV-1 and
pseudovirion preparations were also assayed for their sta-
bility to increasing temperatures. Aliquots of virus stocks
containing 10–20 ng of particle-associated gp120 were re-
suspended in 200 L of PBS containing 0.5% BSA and
incubated at 0, 4, 22, 37, 50, and 65 °C for 2 h. Virions were
then purified as previously described and gp120 content
determined by the gp120 capture ELISA.
Determination of p24 concentration by ELISA
The p24 content of HIV-1 virions and pseudovirion prep-
arations was performed using a p24 antigen capture ELISA.
The murine anti-p24 capture antibody 183-H12-5C was
obtained from Bruce Chesebro and Kathy Wehrly through
the NIH AIDS Research and Reference Reagent Program.
The capture antibody was coated onto 96-well plates at a
dilution of 1:800 in PBS and incubated overnight at 37 °C.
Plates were blocked for 1 h at 37 °C with 5% fetal calf
serum in PBS. The detection of bound p24 was determined
using HIV-Ig, obtained from NABI through the NIH AIDS
Research and Reference Reagent Program, at a dilution of
1:20,000 for 1 h at 37 °C. Colorimetric analysis was per-
formed using the Immunopure TMB Substrate Kit (Pierce,
Rockford, IL) and absorbance was read at 450 nm. Recom-
binant p24 was used for the standard curve and sensitive to
less than 20 pg of p24.
Gradient analysis of virions and pseudovirions
HIV-1 virions or pseudovirions were analyzed by cen-
trifugation on linear 20–60% sucrose gradients. NL4-3 and
NLPr virions were produced by transfecting 10 g of
proviral DNA into 293T cells on 10 cm2 dishes using the
calcium phosphate/BBS transfection method. Pseudovirions
were produced by cotransfecting 4 g of the codon-opti-
mized Pr55Gag or Gag-Pro expression construct along with
4 g of the codon-optimized BaL gp160 expression con-
struct into 293T cells on 10 cm2 dishes using the calcium
phosphate/BBS transfection method. Typically three 10 cm2
dishes of 293T cells were transfected at 30–40% confluence
and incubated at 35 °C, 4% CO2 for 16 h. The cells were
then washed and fresh DMEM applied. Virus and
pseudovirion preparations were metabolically labeled using
75 Ci/ml [35S]cysteine/methionine applied in cysteine-
and methionine-deficient DMEM. Labeled viruses and
pseudovirions were harvested after 24 h, clarified by low-
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speed centrifugation, filtered through a 0.45 m filter, and
then purified by ultracentrifugation through a 20% sucrose
cushion (100,000 g for 3 h, 0 °C). Viral pellets were then
resuspended in 1 mL of PBS with 0.5% BSA, and overlaid
on linear 20–60% sucrose gradients. Ultracentrifugation
was performed at 100,000 g overnight at 0 °C in a Beckman
SW41 rotor. Equal fractions were collected and the density
of each fraction determined using a refractometer. Samples
were subsequently diluted in PBS and disrupted using RIPA
buffer (1% NP-40, 0.1% SDS in PBS) and immunoprecipi-
tated using HIV positive patients’ sera. Analysis was per-
formed by SDS-PAGE and autoradiography, and quantita-
tion performed with the Cyclone Phosphorimager System
(Packard Instrument Co., Meriden, CT).
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